Thyroid hormone analogs and methods of use

Details Thyroid hormone analogs and methods of use Thyroid hormone analogs and methods of use

2005-09-15

2011-12-06

Kishore, Gollamudi (Department: 1612)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C424S489000, C514S506000

Reexamination Certificate

active

08071134

ABSTRACT:
Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

REFERENCES:
patent: 3625214 (1971-12-01), Higuchi
patent: 4205058 (1980-05-01), Wagner et al.
patent: 4650751 (1987-03-01), Siegel et al.
patent: 4789734 (1988-12-01), Pierschbacher
patent: 4801504 (1989-01-01), Burdick et al.
patent: 4801575 (1989-01-01), Pardridge
patent: 4906474 (1990-03-01), Langer et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 4968590 (1990-11-01), Kuberasampath et al.
patent: 5011486 (1991-04-01), Aebischer et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5104895 (1992-04-01), Spinelli et al.
patent: 5225204 (1993-07-01), Chen et al.
patent: 5231000 (1993-07-01), Majocha et al.
patent: 5304121 (1994-04-01), Sahatjian
patent: 5410016 (1995-04-01), Hubbell et al.
patent: 5438126 (1995-08-01), DeGroot et al.
patent: 5591709 (1997-01-01), Lindenbaum
patent: 5593688 (1997-01-01), Baldeschwieler
patent: 5648506 (1997-07-01), Desai et al.
patent: 5766635 (1998-06-01), Spenleuhauer et al.
patent: 6139870 (2000-10-01), Verrecchia
patent: 6316412 (2001-11-01), Ginsberg et al.
patent: 6482406 (2002-11-01), Stewart
patent: 6740680 (2004-05-01), Danforth, Jr. et al.
patent: 6818620 (2004-11-01), Bhatnagar
patent: 7807621 (2010-10-01), Mazar et al.
patent: 2001/0046521 (2001-11-01), Zasloff et al.
patent: 2002/0049247 (2002-04-01), Chen
patent: 2002/0137676 (2002-09-01), Hsiang et al.
patent: 2002/0151594 (2002-10-01), Morkin et al.
patent: 2003/0138557 (2003-07-01), Allison
patent: 2003/0157098 (2003-08-01), Laug
patent: 2003/0162758 (2003-08-01), Schwartz et al.
patent: 2003/0165576 (2003-09-01), Fujii et al.
patent: 2004/0013728 (2004-01-01), Oh et al.
patent: 2004/0033259 (2004-02-01), Hanshew, Jr. et al.
patent: 2005/0249721 (2005-11-01), Houston et al.
patent: 2006/0210539 (2006-09-01), Zhang et al.
patent: 2008/0193377 (2008-08-01), Line et al.
patent: 1126589 (1996-07-01), None
patent: WO 95/00135 (1995-01-01), None
patent: WO 96/40048 (1996-12-01), None
patent: WO 98/33942 (1998-08-01), None
patent: WO 98/56771 (1998-12-01), None
patent: WO 99/62549 (1999-12-01), None
patent: WO-0064431 (2000-11-01), None
patent: WO 00/78815 (2000-12-01), None
patent: WO 01/13936 (2001-03-01), None
patent: WO 02/03914 (2002-01-01), None
patent: WO 02/49501 (2002-06-01), None
patent: WO 02/060389 (2002-08-01), None
patent: WO 03/075741 (2003-09-01), None
patent: WO 2005/027895 (2005-03-01), None
patent: WO 2006/003014 (2006-01-01), None
patent: WO 2006/031922 (2006-03-01), None
patent: WO 2008/051291 (2008-05-01), None
patent: WO-2008140507 (2008-11-01), None
Konno et al., “Antiogenetic therapy for carcinoma”,Igaku No Ayumi, 194(10):824-828 (2000).
Tanaka et al.,J. Soc. Gastroenterological Surgery, 27(2):360 (1996).
Meneses et al., “Recombinant angiostatin prevents retinal neovascularization in a murine proliferative retinopathy model”,Gene Therapy, 8(8):646-648 (2001).
Kuroki et al., “Diabetic retinopathy—The mechanisms of the ocular neovascularization and the development of anti-angiogenic drugs-”,Nippon Rinsho, 57(3):584-589 (1999) (English Abstract).
Brooks et al., “Antiintegrin ανβ3 blocks human breast cancer growth and angiogenesis in human skin”,J. Clin. Invest., 96(4):1815-1822 (1995).
Sato et al., “Neovascularization: General Remarks”,Biotherapy, 15(6):631-636 (2001) (English Abstract).
Kawasuji et al.,Jap. Circ. J., 63(Suppl. 1):65 (1999).
Koyama et al., “Recent Status and Future Perspectives in Therapeutic Angiogenesis”,Prog. Med., 22(12):3070-3076 (2002) (English Abstract).
Sumi et al., “Wound healing using regenerative medicine”,Surg. Front., 10(2):162-165 (2003).
Chinese Office Action for Application No. 2004800331846, mailed Nov. 30, 2007, cites CN 1126589.
Chinese Office Action dated Mar. 5, 2010.
Database Biosis [Online], Accession No. PREV200400161659, Abstract, Mousa et al., “Discovery of pro-angiogenic effects of thyroid hormone and analogs”, &Blood, 102(11):77b-78b (2003).
Pujol et al., “Letter to the editors: Prevention of thyroid neoplasm recurrence with Triac and levothyroxine”,Clin. Endocrinol., 46:121-122 (1997).
Tomanek et al.Cell. Mol. Biol. Res., 40(2):129-136 (1994).
Tomanek et al.Circ. Res., 82(5):587-593 (1998).
Tomanek et al.J. Mol. Cell. Cardiol., 30(5):923-932 (1998).
Wang et al.Am. J. Physiol. Heart Circ. Physiol., 284(2):H613-H618 (2003).
Fife et al., “Effects of tetracyclines on angiogenesis in vitro”, Cancer Letters, 153:75-78 (2000).
Alexis et al., “Nonocclusive Common Carotid Artery Thrombosis in the Rat Results in Reversible Sensorimotor and Cognitive Behavioral Deficits”,Stroke, 26:2338-2346 (1995).
Ali et al., “Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials”,Urology, 57(Suppl 4A):143-147 (2001).
Ali et al., “High levels of oestrogen receptor-α in tumorigenesis: inhibition of cell growth and angiogenic factors”,Cell Prolif., 34(4):223-231 (2001).
Allen, A.R., “Surgery of experimental lesion of spinal cord equivalent to crush injury of fracture dislocation of spinal column”,J. Am. Med. Assoc., 57(11):878-880 (1911).
Amirkhosravi et al., “Antimetastatic effect of tinzaparin, a low-molecular-wight heparin”,J. Thromb. Haemost., 1:1972-1976 (2003).
Amirkhosravi et al., “Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454”,J. Thrombosis and Haemostasis, 3:549-554 (2003).
Audus et al., “Bovine Brain Microvessel Endothelial Cell Monolayers as a Model System for the Blood-Brain Barrier”, in Biological Approaches to the Controlled Delivery of Drugs,Ann. N.Y. Acad. Sci., 507:9-18 (1987).
Avis, K.E., “Parenteral Preparations”, inRemington's Pharmaceutical Sciences, 15thEd., Chapter 84, pp. 1461-1487, Mack Publishing Co., Easton, Pennsylvania (1975).
Bederson et al., “Rat Middle Cerebral Artery Occlusion: Evaluation of the Model and Development of a Neurologic Examination”,Stroke, 17(3):472-476 (1986).
Benedetti et al., “Life Tables and Survivor Functions”, in BMDP Statistical Software Manual, BMDP Statistical Software, Inc., vol. 2, p. 573 and 689-718 (1988).
Bennett et al., “A peptide derived from α-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen”,Proc. Natl. Acad. Sci. USA, 99(4):2211-2215 (2002).
Bergh et al., “Integrin ανβ3contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis”,Endocrinol., 146(7):2864-2871 (2005).
Bergstrom et al., “Iodine-123 labelled Z-(R,R)-IQNP: a potential radioligand for visualization of M1and M2muscarinic acetylcholine receptors in Alzheimer's disease”,Eur. J. Nucl. Med., 26(11):1482-1485 (1999).
Bhat et al., “NCAM-180, the largest component of the neural cell adhesion molecule, is reduced in dysmyelinating quaking mutant mouse brain”,Brain Res., 452:373-377 (1988).
Blight, A.R., “Macrophages and Inflammatory Damage in Spinal Cord lnjury”,J. Neurotrauma, 9(Suppl. 1):S83-S91 (1992).
Blood et al., “Tumor interactions with the vasculature: angiogenesis and tumor metastasis”,Bioch. Biophys. Acta, 1032:89-118 (1990).
Bornebroek et al., “Potential for imaging cerebral amyloid deposits using123I-labelled serum amyloid P component and SPET”,Nucl. Med. Commun., 17:929-933 (1996).
Bozarth et al., “An improved method for the quantitation of cellular migration: Role of ;

Affiliated with

Also associated with

Rating

Thyroid hormone analogs and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thyroid hormone analogs and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thyroid hormone analogs and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4313689